Journal article icon

Journal article

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

Abstract:

Ibandronate is a highly potent, nitrogen-containing bisphosphonate. Unlike most other bisphosphonates, it is under clinical development for both oral and intravenous (i.v.) administration. Ibandronate can be used in convenient intermittent regimens that may optimize therapeutic outcome with enhanced compliance by patients. The preclinical pharmacokinetics (PK) and pharmacology of ibandronate have been extensively explored in a large preclinical development program involving various recommende...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s00198-004-1612-7

Authors


Journal:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Volume:
15
Issue:
6
Pages:
423-433
Publication date:
2004-06-05
DOI:
EISSN:
1433-2965
ISSN:
0937-941X
URN:
uuid:c0810372-32b8-4ed6-a048-fa3e1295051f
Source identifiers:
109144
Local pid:
pubs:109144

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP